5 Best Innovative Healthcare Stocks to Buy Now

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 72

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list.

TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares. The adjustment was included in a broader healthcare sector update, where HSBC reviewed the potential for relative sector strength in the second half of the year. The firm highlighted therapeutics as offering attractive risk-adjusted opportunities, identified life sciences tools as a potential beneficiary of a cyclical recovery, and noted that medical technology companies appear undervalued.

Earlier on June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the U.S. Food and Drug Administration and European Medicines Agency accepted regulatory submissions for cemdisiran as a potential treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The FDA granted the application Priority Review, with a target decision expected in November 2026 following the use of a priority review voucher. A European Commission decision is anticipated during the second half of 2027. The regulatory filings are supported by results from the Phase 3 NIMBLE study, which evaluated subcutaneous dosing of cemdisiran every 12 weeks in adults with symptomatic gMG, including patients who may also receive standard immunosuppressive therapies.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biopharmaceutical company developing life-changing medicines for serious diseases. It leverages advanced genetic research, data analytics, and proprietary platforms like VelociSuite, Regeneron Genetics Center, and genetic medicine technologies to accelerate drug discovery and create targeted therapies.